Evidence map›Paper›PMID 29720199›Full record

ArticleJournal of nanobiotechnology2018

Immunoassays for scarce tumour-antigens in exosomes: detection of the human NKG2D-Ligand, MICA, in tetraspanin-containing nanovesicles from melanoma.

Sheila López-Cobo, Carmen Campos-Silva, Amanda Moyano, Myriam Oliveira-Rodríguez, Annette Paschen, María Yáñez-Mó, María Carmen Blanco-López, Mar Valés-Gómez

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 81 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Recent developments in biosensing methods for extracellular vesicle protein characterization.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Sheila López-CoboDepartment of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.
Carmen Campos-SilvaDepartment of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.
Amanda MoyanoDepartment of Physical and Analytical Chemistry, University of Oviedo, Asturias, Spain.
Myriam Oliveira-RodríguezDepartment of Physical and Analytical Chemistry, University of Oviedo, Asturias, Spain.
Annette PaschenDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen, and German Cancer Consortium (DKTK) Partner Site Essen/Düsseldorf, 45122, Essen, Germany.
María Yáñez-MóDepartment of Molecular Biology, UAM, Madrid, Spain.
María Carmen Blanco-LópezDepartment of Physical and Analytical Chemistry, University of Oviedo, Asturias, Spain.
Mar Valés-GómezDepartment of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain. mvales@cnb.csic.es.ORCID http://orcid.org/0000-0001-7424-3206
Centro Nacional de Biotecnología · ESUniversidad de Oviedo · ESCentro de Biología Molecular Severo Ochoa · ESDüsseldorf University Hospital · DE

Funding

Consejería de Sanidad, Comunidad de Madrid S2010/BMD-2326GEIVEX Travel grant 2016Gobierno del Principado de Asturias GRUPIN14-022Ministerio de Economía y Competitividad MAT2017-84959-C2-1-RMinisterio de Economía y Competitividad Rediex Network of ExcellenceMinisterio de Economía y Competitividad SAF2015-69169-R
6 · The paper itself

Abstract

backgroundTumour-derived exosomes can be released to serum and provide information on the features of the malignancy, however, in order to perform systematic studies in biological samples, faster diagnostic techniques are needed, especially for detection of low abundance proteins. Most human cancer cells are positive for at least one ligand for the activating immune receptor NKG2D and the presence in plasma of NKG2D-ligands can be associated with prognosis.

methodsUsing MICA as example of a tumour-derived antigen, endogenously expressed in metastatic melanoma and recruited to exosomes, we have developed two immunocapture-based assays for detection of different epitopes in nanovesicles. Although both techniques, enzyme-linked immunosorbent assay (ELISA) and Lateral flow immunoassays (LFIA) have the same theoretical basis, that is, using capture and detection antibodies for a colorimetric read-out, analysis of exosome-bound proteins poses methodological problems that do not occur when these techniques are used for detection of soluble molecules, due to the presence of multiple epitopes on the vesicle.

resultsHere we demonstrate that, in ELISA, the signal obtained was directly proportional to the amount of epitopes per exosome. In LFIA, the amount of detection antibody immobilized in Au-nanoparticles needs to be low for efficient detection, otherwise steric hindrance results in lower signal. We describe the conditions for detection of MICA in exosomes and prove, for the first time using both techniques, the co-existence in one vesicle of exosomal markers (the tetraspanins CD9, CD63 and CD81) and an endogenously expressed tumour-derived antigen. The study also reveals that scarce proteins can be used as targets for detection antibody in LFIA with a better result than very abundant proteins and that the conditions can be optimized for detection of the protein in plasma.

conclusionsThese results open the possibility of analyzing biological samples for the presence of tumour-derived exosomes using high throughput techniques.

Indexed as

Antigens, NeoplasmCell Line, TumorExosomesHistocompatibility Antigens Class IHumansImmunoassayMelanomaNanoparticlesNK Cell Lectin-Like Receptor Subfamily KTetraspaninsAntigens, NeoplasmHistocompatibility Antigens Class IKLRK1 protein, humanMHC class I-related chain ANK Cell Lectin-Like Receptor Subfamily KTetraspaninsAggregationExosomesImmune captureLateral flowSteric hindranceTumour antigens

Identifiers

PMID29720199
PMCPMC5932892
OpenAlexW2804046341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.